Protalix BioTherapeutics(PLX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, August 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for t ...